Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9057 - 9064 of 12143 results
FTC Answers the Call for Guidance Regarding Antitrust Compliance for State Regulatory Boards Controlled by Market Participants
October 19, 2015| Alert| Viewpoint
FTC Submits Public Comments to States Considering Regulations of Cooperative Agreements Between Hospitals
October 19, 2015| Blog| Viewpoint
FTC Provides Guidance Regarding Antitrust Compliance for State Regulatory Boards
October 19, 2015| Blog| Viewpoint
Congress Contemplates Renewable Energy Tax Credits
October 16, 2015| Blog| Viewpoint
EU Data Protection Authorities Issue Joint Statement on Invalidation of Safe Harbor: Not Much Help Here
October 16, 2015| Blog| Viewpoint
California Becomes Latest State to Pass Biosimilar Substitution Law
October 16, 2015| Blog| Viewpoint
OCR Launches Platform for Developer HIPAA Questions
October 16, 2015| Blog| Viewpoint
FDA to Host First Public Meeting on Biotech Regulation Overhaul
October 15, 2015| Blog| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts
Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|